{"resourceType": "Evidence", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/367928", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03640312-otherOutcomeMeasure-0--OG001", "assigner": {"display": "Computable Publishing LLC"}}], "name": "NCT03640312_otherOutcomeMeasure_0_OG001", "title": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312", "status": "active", "variableDefinition": [{"description": "Candesartan", "note": [{"text": "Outcome Measure Population Description: All randomized participants"}, {"text": "Outcome Measure Denominator Units: Participants"}], "variableRole": "population", "observed": {"identifier": {"type": {"text": "ClinicalTrials.gov Outcome Measurement Group Id"}, "value": "OG001"}, "display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}}, {"variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03640312-otherOutcome-0", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks -  (NCT03640312)", "reference": "EvidenceVariable/367896"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-MeasureParam", "code": "COUNT_OF_PARTICIPANTS", "display": "Count of Participants"}]}, "quantity": {"value": 0, "unit": "Participants"}, "sampleSize": {"knownDataCount": 30}, "attributeEstimate": [{"type": {"text": "Percentage"}, "quantity": {"value": 0, "unit": "%"}}]}], "id": "367928", "meta": {"versionId": "8", "lastUpdated": "2025-06-05T17:39:08.147Z"}, "url": "https://fevir.net/resources/Evidence/367928", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367928. Revised 2025-06-05. Available at: https://fevir.net/resources/Evidence/367928. Computable resource at: https://fevir.net/resources/Evidence/367928#json.", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}